08 Sep 2022 Governance

Statement from Leukaemia UK on the death of Her Majesty Queen Elizabeth II

On behalf of the Leukaemia UK team, Chair of Trustees, Chris Corbin OBE, has made the following statement:

“We are extremely saddened to hear the news of the death of Her Majesty Queen Elizabeth II.

Together with the nation and people around the world, we remember a true leader who gave her life to duty. The Queen’s dedication, diligence and integrity were an inspiration to all and we are thankful for an inspiring monarch, who gave her life in service of her country and the Commonwealth.

The Queen’s support for the charity sector has enabled charities in the UK to thrive during her reign and will have a lasting impact for those whom the charities support. 

We share our condolences with the entire Royal Family and especially the Queen’s children and grandchildren. Our thoughts are with them at this very difficult time.” 

Related posts

New campaign launches for the forgotten 500,000 families

17 October 2022

New campaign launches for the forgotten 500,000 families

Patient groups, charities and clinicians unite to raise awareness of half a million vulnerable people, many of whose lives have never returned to normal after the Covid-19 lockdown. A new…

A record year for Leukaemia UK London Marathon runners

21 September 2022

A record year for Leukaemia UK London Marathon runners

62 runners put their best feet forward for Leukaemia UK A record 62 runners are taking part in this year’s London marathon to help fund vital research into leukaemia diagnosis,…

World Blood Cancer Day interview with Dr Pramila Krishnamurthy

18 May 2022

World Blood Cancer Day interview with Dr Pramila Krishnamurthy

On 28th May the global blood cancer community comes together to mark World Blood Cancer Day, this campaign calls for support of those with blood cancer and encourages people to become stem cell donors.

A new clinical trial announced

21 May 2020

A new clinical trial announced

A study into the impact of severe covid-19 infection on patients who receive stem cell transplants for blood cancers and blood disorders.